By George Ongkojoyo 
Pancreatic ductal adenocarcinoma (PDAC) has long remained one of the most formidable challenges in modern oncology, characterized by a lack of early diagnostic markers and a profound resistance to conventional therapies. However, a landmark study published in Nature Communications has provided what researchers describe as the most comprehensive immune map of pancreatic cancer to date, offering a potential breakthrough in how clinicians approach the disease. Led by Associate Professor Shivan Sivakumar from the University of Birmingham and Associate Professor Rachael Bashford-Rogers from the University of Oxford, the research identifies distinct immune microenvironments within tumours, suggesting that the future of treatment lies in precision immunotherapy tailored to the specific cellular makeup of a patient’s cancer.
The study’s core finding revolves around the discovery that pancreatic tumours are not a monolith; rather, they exhibit varying patterns of immune cell infiltration. While some tumours show a higher presence of T cells, others are dominated by myeloid cells, such as macrophages. This distinction is critical because it explains why current "one-size-fits-all" immunotherapies, particularly checkpoint inhibitors, have largely failed in treating pancreatic cancer. By understanding the specific "cellular census" of a tumour, researchers believe they can now design therapies that either boost helpful immune responses or deplete the suppressive cells that allow the cancer to hide from the body’s natural defenses.
The Challenge of the Pancreatic Immune Landscape
For decades, pancreatic cancer has been categorized as a "cold" tumour, meaning it does not typically provoke a strong immune response. In many other forms of cancer, such as melanoma or certain types of lung cancer, the immune system recognizes the tumour as a foreign threat and sends T cells to attack it. Checkpoint inhibitors work by "releasing the brakes" on these T cells, allowing them to destroy the malignancy. In pancreatic cancer, however, these brakes are often irrelevant because the T cells are either absent from the tumour site or are rendered completely inactive by a hostile microenvironment.
Dr. Shivan Sivakumar, Associate Professor of Oncology at the University of Birmingham and the study’s lead author, noted that the lack of immunogenic reaction is a primary hurdle. "Pancreatic cancer is a tumour that does not respond to existing immunotherapies," Dr. Sivakumar explained. "A basis for this is that there is not the same immunogenic reaction to the tumour that exists in other cancers. We therefore mapped out how the immune system is constructed in pancreatic cancer patients. This has helped us understand with a high degree of confidence what immune cells are present and let us see how the tumour evades the immune system."
The mapping process revealed that the evasion tactics used by pancreatic tumours are highly sophisticated. The research team identified that the tumour microenvironment (TME) creates a physical and chemical shield. In some patients, this shield is maintained by myeloid-derived suppressor cells and macrophages that actively "switch off" any T cells that manage to penetrate the tumour. In others, the T cells are simply excluded from the tumour core entirely.
Methodology: A Multi-Omics Approach to Mapping
To achieve this level of detail, the research team utilized a sophisticated suite of technologies known as single-cell multi-omics. They analyzed cells from twelve patients, creating a high-resolution map of both tumour-infiltrating immune cells and peripheral immune cells found in the blood. This was not merely a count of cell types; the researchers conducted gene expression analysis, single-cell T-cell receptor (TCR) and B-cell receptor (BCR) sequencing, and identified specific proteins expressed on the surface of these cells.
By looking at the TCR and BCR sequences, the team could track the "lineage" and "experience" of the immune cells—essentially seeing which cells had previously encountered the tumour and how they had reacted. This granular data allowed them to see the diversity of the immune response in a way that traditional bulk sequencing could not. To ensure the robustness of their findings, the Birmingham and Oxford team then cross-referenced their results with two other large, publicly available pancreatic cancer datasets, confirming that the patterns they observed were consistent across broader populations.
Associate Professor Rachael Bashford-Rogers, a senior author from the University of Oxford, emphasized the technological leap this study represents. "By leveraging single-cell multi-omics and novel computational approaches, this study identifies potential strategies such as boosting certain cell responses and depleting suppressive immune cells to enhance immune-based treatments," she stated. The ability to distinguish between different immune environments—specifically those rich in B and T cells versus those dominated by suppressive myeloid cells—provides a roadmap for patient stratification in future clinical trials.
Identifying New Therapeutic Targets: TIGIT and CD47
One of the most promising outcomes of the study is the identification of specific molecular targets that could be exploited by new drugs. The research gave significant weight to TIGIT (T-cell immunoreceptor with Ig and ITIM domains), a protein that acts as an immune checkpoint. While TIGIT was already a known target of interest in oncology, this study provides the evidence needed to prioritize it for pancreatic cancer, particularly in patients whose tumours show T-cell infiltration but remain suppressed.
Furthermore, the study highlighted CD47 as a critical target. CD47 is often referred to as the "don’t eat me" signal. Cancer cells frequently overexpress CD47 on their surface to tell macrophages—the immune system’s "cleaner" cells—not to attack them. In tumours found to be rich in myeloid cells, blocking CD47 could effectively "unmask" the cancer cells, allowing macrophages to engulf and destroy them. This macrophage-based therapy represents a significant shift from the T-cell-centric focus of the last decade of immunotherapy.
The researchers also identified the role of activated regulatory T cells (Tregs) and B cells. Tregs typically function to prevent the immune system from attacking the body’s own healthy tissues, but in the context of a tumour, they are "recruited" by the cancer to suppress the anti-tumour immune response. The study suggests that depleting these intratumoural Tregs could lower the tumour’s defenses. Meanwhile, strategies to boost B-cell responses could enhance the body’s ability to produce antibodies against the tumour, providing a multi-pronged attack.
The Grim Reality of Pancreatic Cancer Statistics
The urgency of this research is underscored by the devastating statistics associated with the disease. Pancreatic cancer remains one of the deadliest malignancies globally. In England, the survival rate beyond ten years was less than 1% for patients diagnosed between 2013 and 2017. Because the pancreas is located deep within the abdomen, tumours often grow for a long time without causing noticeable symptoms. By the time physical signs such as jaundice, weight loss, or abdominal pain appear, the cancer has often metastasized or wrapped itself around major blood vessels, making surgical removal impossible.
"As an honorary consultant in medical oncology focused on pancreatic, liver and biliary tract cancers, I am perhaps more familiar than most with the devastating nature of this disease," Dr. Sivakumar said. He noted that according to Pancreatic Cancer UK, the disease is the fifth biggest cancer killer in the United Kingdom, claiming approximately 9,000 lives annually. The five-year survival rate remains stubbornly low, at less than 7% for all common cancers.
Even for the small minority of patients—roughly 10%—who are diagnosed early enough to be eligible for surgery, the outlook remains precarious. The recurrence rate after surgical intervention is over 80%, suggesting that microscopic cancer cells often remain in the body or that the systemic environment remains highly conducive to tumour regrowth.
Future Directions: mRNA Vaccines and Precision Trials
The insights gained from the immune map are already being put into practice. The University of Birmingham is currently participating in a high-profile mRNA vaccine study for pancreatic cancer. These vaccines are designed to teach the patient’s immune system to recognize "neoantigens"—mutated proteins found only on the surface of their specific tumour cells. The goal is to use these vaccines post-surgery to eliminate any residual cancer cells and prevent the high rate of recurrence that currently plagues patients.
In addition to the vaccine trials, the Birmingham team is preparing to open two further clinical studies. These "investigator-initiated" trials will use the precision insights from the Nature Communications study to match patients with therapies that target their specific immune profile. This could involve using CD47 blockers for those with myeloid-heavy tumours or TIGIT inhibitors for those with T-cell-rich environments.
The role of the private sector and the pharmaceutical industry is also central to this transition. By identifying clear targets like CD47 and TIGIT, the research provides a "de-risked" path for drug developers to invest in pancreatic cancer treatments, which have historically seen a high failure rate in clinical trials.
A Foundation for a New Era of Treatment
The researchers believe that their data provides a necessary foundation for understanding why immunotherapy has failed in the past and how it can succeed in the future. By moving away from the idea that all pancreatic cancers are the same, the medical community can begin to offer "tailored interventions."
The geographic and institutional significance of the research was also highlighted. Birmingham is a major hub for pancreatic treatment, with over 150 operations occurring annually. This high volume of cases provides a unique environment for translational research—where findings in the lab can be quickly moved into clinical settings to impact patient care.
As Dr. Sivakumar concluded, "Any potential breakthroughs in pancreatic cancer treatment are therefore so important. Armed with the insights we have gained from this study and others, we are now constructing our own studies to help see if we can use precision immunotherapeutics to help provide good treatment options for these patients."
The study marks a pivotal moment in the fight against a disease that has long been considered untreatable for many. While widespread clinical application of these findings may still be several years away, the "immune map" provides the most detailed GPS yet for navigating the complex and hostile landscape of pancreatic cancer, offering a glimmer of hope for thousands of patients diagnosed each year.
